title: Therapeutic potential and critical analysis of trastuzumab and bevacizumab in combination with different chemotherapeutic agents against metastatic breast/colorectal cancer affecting various endpoints.
abstract: Researchers are working day and night across the globe to eradicate or at least lessen the menace of cancer faced by the mankind. The two very frequently occurring cancers faced by the human beings are metastatic breast cancer and metastatic colorectal cancer. The various chemotherapeutic agents like anthracycline, cyclophosphamide, paclitaxel, irinotecan, fluorouracil and leucovorin etc., have been used impressively for long. But the obstinate character of metastatic breast cancer and metastatic colorectal cancer needs more to tackle the threat. So, the scientists found the use of monoclonal antibodies trastuzumab (Herceptin(®)) and bevacizumab (Avastin(®)) for the same. The current study critically investigates the therapeutic potential of trastuzumab and bevacizumab in combination with various chemotherapeutic agents against metastatic breast cancer and metastatic colorectal cancer. To the best of our knowledge, this is the very first critical analysis showing percent wise increase in various positive endpoints like median time to disease progression, median survival, and progression free survival etc. for the treatment of metastatic breast/colorectal cancer using trastuzumab and bevacizumab in combination with different chemotherapeutic agents and provides the rational for the success and failure of the selected monoclonal antibodies.
authors.affiliation: Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia (A Central University), New Delhi 110025, India; Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan 45142, Saudi Arabia.
authors.forename: Mohd
authors.initials: M
authors.lastname: Wahid
authors.affiliation: Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan 45142, Saudi Arabia; Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raibareli Road, Lucknow 226014, UP, India.
authors.forename: Raju K
authors.initials: RK
authors.lastname: Mandal
authors.affiliation: Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan 45142, Saudi Arabia; Division of Gynecology Oncology, Women's Health Services, Henry Ford Hospital, Detroit, MI 48202, USA.
authors.forename: Sajad A
authors.initials: SA
authors.lastname: Dar
authors.affiliation: Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan 45142, Saudi Arabia; GE Healthcare, Sector-43, Gurgaon 122002, Haryana, India.
authors.forename: Arshad
authors.initials: A
authors.lastname: Jawed
authors.affiliation: Department of Biosciences, Integral University, Lucknow 226026, UP, India.
authors.forename: Mohtashim
authors.initials: M
authors.lastname: Lohani
authors.affiliation: Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan 45142, Saudi Arabia.
authors.forename: Mohammad Y
authors.initials: MY
authors.lastname: Areeshi
authors.affiliation: Hewitt Laboratory of the Ola B. Williams Glaucoma Center, Department of Ophthalmology, Storm Eye Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
authors.forename: Naseem
authors.initials: N
authors.lastname: Akhter
authors.affiliation: Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan 45142, Saudi Arabia; Department of Biosciences, Jamia Millia Islamia (A Central University), New Delhi 110025, India; Centre for Drug Research (CDR), Faculty of Pharmacy, Viikki Biocentre-2, University of Helsinki, PO Box 56 (Viikinkaari 5E), FI-00014 Helsinki, Finland. Electronic address: shafiul.haque@hotmail.com.
authors.forename: Shafiul
authors.initials: S
authors.lastname: Haque
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068878:Trastuzumab / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000068878:Trastuzumab
keywords: Anthracycline; Bevacizumab; Cyclophosphamide; Fluorouracil; Irinotecan; Leucovorin; Metastatic breast cancer; Metastatic colorectal cancer; Paclitaxel; Trastuzumab